STOCK TITAN

KalVista Pharmaceuticals, Inc. - $KALV STOCK NEWS

Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: $KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KalVista Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KalVista Pharmaceuticals's position in the market.

Rhea-AI Summary
KalVista Pharmaceuticals to present at Cantor Global Healthcare Conference on September 27th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
Rhea-AI Summary
KalVista Pharmaceuticals achieves target enrollment for Sebetralstat Phase 3 trial, data readout on track for Q4. Preparations continue for NDA filing in H1 2024 and rapid commercialization upon approval. Key hires and real-world patient data support the efficacy of Sebetralstat. R&D expenses increased to $19.3 million, G&A expenses increased to $9.8 million. Net loss of $25.3 million. Cash position at $123.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals accepted multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting. They will also be launching a new patient-focused site called 'Mind the HAE Attack' at HAEi EMEA on September 1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Nicole Sweeny as Chief Commercial Officer. With the company's pivotal KONFIDENT data coming in Q4 of this year and the NDA in the first half of 2024, the addition of Sweeny, a seasoned professional with over 20 years of commercial strategy and leadership experience, is expected to further develop the growing commercial organization. Her expertise in all aspects of commercializing products in hereditary angioedema (HAE) will be invaluable as the company moves towards the expected worldwide launch of sebetralstat, the first oral, on-demand HAE therapy. Sweeny's previous experience in launching approved products for rare diseases, including HAE, makes her a valuable addition to KalVista's team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
Rhea-AI Summary
KalVista Pharmaceuticals has announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit. The presentations will focus on the earliest recognition of HAE attack onset, the importance of early on-demand treatment, and the preferences of people with Hereditary Angioedema for on-demand treatment. The presentations will take place on July 21 from 9:50 -10:20 am EDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
KalVista Pharmaceuticals, Inc.

Nasdaq:KALV

KALV Rankings

KALV Stock Data

513.43M
24.12M
1.14%
92.16%
13.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About KALV

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.